Impact of ExtraCorporeal Phototherapy (ECP) on Auxiliary Follicular T-lymphocytes and Circulating B-lymphocytes During Chronic AntiBody-Mediated Rejection in Kidney Transplantation: IPECAM
Trial Snapshot
- Phase
- Not Applicable
- Status
- Recruiting
- Sponsor
- Enrollment
- 30
- Locations
- 4
- Primary Endpoint
- Frequency of TFH cells and their activation markers
Study Overview
Brief Summary
Chronic AntiBody-Mediated Rejection (cABMR) is the leading cause of late kidney transplant loss (after 1 year of kidney transplantation). Its therapeutic management is poorly codified and there is currently no treatment referring.
Extracorporeal phototherapy (ECP) is a therapeutic apheresis that involves purifying mononucleated cells in the blood, exposing them to UltraViolet A (UVA) and re-injecting them to the patient. This treatment is used as common care in the first line as part of the treatment of cutaneous T lymphoma and in the second line as part of the graft versus host reaction after bone marrow allograft.
The mechanisms underlying the action of the ECP are not well known. They are mediated by the reinjection of cells exposed to UVA which enter apoptosis and induce immunomodulation. Recent work during cABMR shows that TFH lymphocytes, the maturing population of B lymphocytes, are deregulated and activated.
The hypothesis is that ECP can modulate T Follicular Helper (TFH) lymphocytes during cABMR.
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Other
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •ECP treatment decision based on transplant team habits (care management)
- •Age ≥ 18 years
- •Affiliation to a French social security scheme
- •Kidney transplant at least 6 months prior to inclusion
- •cABMR proven by a renal graft biopsy less than 3 months and meeting the following histological criteria:
- •allograft glomerulopathy (cg>0, and maximum score cg2) or intimal fibrosis
- •C4d positive or ptc+g greater than or equal to 2
- •Presence of Donor Specific Antibody (DSA)
- •Interstitial Fibrosis and Tubular Atrophy (IFTA) less than or equal to 2
- •Glomerular filtration rate > 30 mL/min/1.73 m2
- •Signed informed consent to participate in the study
Exclusion Criteria
- •Active infection or infection with hepatitis B, C or HIV virus
- •Pregnant, breastfeeding or parturient woman
- •Person deprived of liberty by judicial or administrative decision
- •Person receiving psychiatric care under duress
- •Person subject to legal protection
- •Person out of state to express consent
Arms & Interventions
Extracorporeal phototherapy
Intervention: Extracorporeal phototherapy (Other)
Outcomes
Primary Outcomes
Frequency of TFH cells and their activation markers
Time Frame: From the 1st session of ECP to 1 year after the 1st session
Variation in the frequency of TFH cells and their activation markers under treatment.
Secondary Outcomes
- Concentration of circulating B-cell populations(From the 1st session of ECP to 1 year after the 1st session)
- Concentration of pro and anti-inflammatory cytokines(From the 1st session of ECP to 1 year after the 1st session)
- Measurement of genetic markers in TFH cells(At 1 week of the 1st session of ECP and at 3 month after the 1st session)
- Subsequent ECP response in patients with cABMR(3 months of treatment per ECP)
- Comparison of clinical data of patients(From the 1st session of ECP to 1 year after the 1st session)
- Comparison of biological data of patients(From the 1st session of ECP to 1 year after the 1st session)